Literature DB >> 3970468

Late relapse among patients treated for Hodgkin's disease.

T S Herman, R T Hoppe, S S Donaldson, R S Cox, S A Rosenberg, H S Kaplan.   

Abstract

Of 1360 consecutive patients with Hodgkin's disease treated at Stanford University, 1312 patients (96%) had complete remission, but 424 patients had a relapse. Fifty-five patients had relapses 36 months or more after completion of therapy. The actuarial risk of relapse in patients disease-free 3 years after therapy was 12.9%. The occurrence of late relapse was significantly related to stage I disease and nodular sclerosis histologic subtype. Late relapse was detected in 88% of patients by history, physical findings, or chest radiographs. Most patients with stage III and IV disease had late relapses in previously irradiated nodes or extranodally, but patients with stage I and II disease had late relapses primarily in unirradiated nodes. Disease-free survival after salvage therapy for late relapse was similar to that seen after treatment of earlier relapse. Prolonged surveillance of patients for late relapse is necessary after treatment of patients with Hodgkin's disease.

Entities:  

Mesh:

Year:  1985        PMID: 3970468     DOI: 10.7326/0003-4819-102-3-292

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

Review 1.  Clinical aspects of Hodgkin's disease.

Authors:  G M Mead; J M Whitehouse
Journal:  BMJ       Date:  1988-12-17

2.  Hodgkin's disease of the epididymis and testis.

Authors:  J Glaholm; M Brada; A Horwich
Journal:  J R Soc Med       Date:  1989-09       Impact factor: 18.000

3.  Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.

Authors:  Francesco Gaudio; Annamaria Giordano; Vincenzo Pavone; Tommasina Perrone; Paola Curci; Domenico Pastore; Mario Delia; Clara De' Risi; Alessandro Spina; Vincenzo Liso; Giorgina Specchia
Journal:  Adv Hematol       Date:  2010-12-29

Review 4.  Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.

Authors:  Maja Dam Andersen; Stephen Hamilton-Dutoit; Lena Modvig; Maja Vase; Ilse Christiansen; Jacob Haaber Christensen; Rasmus Bo Dahl-Sørensen; Danny Stoltenberg; Peter Kamper; Francesco d'Amore
Journal:  Br J Haematol       Date:  2022-04-08       Impact factor: 8.615

5.  Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.

Authors:  Theodoros P Vassilakopoulos; Evrydiki Kravvariti; Fotios Panitsas; Maria K Angelopoulou; Athanasios Liaskas; Flora N Kontopidou; Xanthoula Yiakoumis; Eleni Variami; Maria N Dimopoulou; Marina P Siakantaris; John V Asimakopoulos; Maria Arapaki; Maria Dimou; Panagiotis Diamantopoulos; Sotirios Sachanas; Chrysovalantou Chatzidimitriou; Marina Belia; Elianna Konstantinou; George Boutsikas; Kyriaki Petevi; Alexandros Kanellopoulos; Styliani Kokoris; Marie-Christine Kyrtsonis; Nora-Athina Viniou; Eleftheria Lakiotaki; Gerasimos Tsourouflis; Penelope Korkolopoulou; Kostas Konstantopoulos; Panayiotis Panayiotidis; Gerassimos A Pangalis
Journal:  Blood Cancer J       Date:  2022-07-05       Impact factor: 9.812

6.  Changing patterns of relapse in Hodgkin's disease.

Authors:  G Duchesne; J Crow; S Ashley; M Brada; A Horwich
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.